Change from baseline to week 24 in QLQ-C30 GHS/QoL and EQ-5D VAS and utility scores
| . | QLQ-C30 GHS/QoL score . | EQ-5D VAS score . | EQ-5D utility score . | |||
|---|---|---|---|---|---|---|
| Pembrolizumab n = 146 . | BV n = 150 . | Pembrolizumab n = 146 . | BV n = 150 . | Pembrolizumab n = 146 . | BV n = 150 . | |
| Baseline score, mean (SD) | 68.2 (18.1) | 67.0 (20.2) | 71.3 (17.9) | 71.2 (17.9) | 0.79 (0.19) | 0.76 (0.20) |
| Week 24, mean score (SD) | 76.5 (16.9) | 69.1 (17.1) | 80.5 (15.1) | 76.9 (15.5) | 0.83 (0.17) | 0.76 (0.18) |
| Change from baseline | ||||||
| LSM change from baseline (95% CI) | 7.29 (3.94-10.64) | −1.31 (−5.17 to 2.55) | 8.53 (5.42-11.64) | 2.41 (−1.05 to 5.87) | 0.04 (0.00-0.08) | −0.05 (−0.09 to −0.01) |
| LSM difference (95% CI) | 8.60 (3.89-13.31); P = .0004 | 6.12 (1.91-10.34); P = .0046 | 0.09 (0.04-0.14); P = .0004 | |||
| . | QLQ-C30 GHS/QoL score . | EQ-5D VAS score . | EQ-5D utility score . | |||
|---|---|---|---|---|---|---|
| Pembrolizumab n = 146 . | BV n = 150 . | Pembrolizumab n = 146 . | BV n = 150 . | Pembrolizumab n = 146 . | BV n = 150 . | |
| Baseline score, mean (SD) | 68.2 (18.1) | 67.0 (20.2) | 71.3 (17.9) | 71.2 (17.9) | 0.79 (0.19) | 0.76 (0.20) |
| Week 24, mean score (SD) | 76.5 (16.9) | 69.1 (17.1) | 80.5 (15.1) | 76.9 (15.5) | 0.83 (0.17) | 0.76 (0.18) |
| Change from baseline | ||||||
| LSM change from baseline (95% CI) | 7.29 (3.94-10.64) | −1.31 (−5.17 to 2.55) | 8.53 (5.42-11.64) | 2.41 (−1.05 to 5.87) | 0.04 (0.00-0.08) | −0.05 (−0.09 to −0.01) |
| LSM difference (95% CI) | 8.60 (3.89-13.31); P = .0004 | 6.12 (1.91-10.34); P = .0046 | 0.09 (0.04-0.14); P = .0004 | |||